HealthCNBC Techabout 2 hours ago
Colossal Biosciences Raises $200 Million Series C
5 min read
Colossal Biosciences CEO Ben Lamm announced a $200 million Series C funding round in July led by TWG Global, raising the company's valuation to $10.2 billion. The firm pursues de-extinction projects like the dire wolf and woolly mammoth, with a birth target in the 2030s, while developing synthetic biology tools for human healthcare and climate change solutions.
Level
Hype check
Tap to vote and see what everyone thinks.
